

Conjugate Vaccine: Challenges during process development, regulatory aspects and scale-up

Suresh Beri

Additional Director (Conjugate Vaccines), Serum Institute of India Pvt Limited, 212, Hadapsar, Pune 411 028, Maharashtra, INDIA

Abstract

The challenges in vaccine development are not only to identify the suitable antigen, its efficacy, pre-clinical and clinical evaluation. The late stage developments like process development, regulatory aspects and scale up possess different sets of challenges to commercialize the vaccine. Manufacturing process for conjugate vaccines is very complex and has various biological and chemical steps. The presentation will focus on the design of experiments, critical process parameters for process development and scale up for commercial manufacturing for conjugate vaccines.

Speaker Biography:

Suresh Beri has completed his PhD in 1996 from Indian Institute of Technology (IIT), Bombay, Mumbai, India in Chemistry. He has worked with leading Indian pharmaceutical companies, Sun Pharmaceutical Limited from 1996-98, Wockhardt Limited 1998-2002 in R&D department and developed process for synthetic hormonal peptides (LHRH analogues and Somatostatin analogue) used in the Oncology for treatment of various cancers. He is working with Serum Institute of India Pvt Limited (SIIPL), vaccine manufacturing company, in conjugate vaccine department since 2002. He has developed the process for Meningococcal A conjugate vaccine (MenAfrivac) and Haemophilus Influenzae type b conjugate vaccine. Currently he is working as an Additional Director at SIIPL.

[40th Global Summit and Expo on Vaccines & Immunology](#)

May 18-19, 2020 Paris, France